New Two-Pronged cancer drug enters key Dose-Finding trial
NCT ID NCT07057791
Summary
This study aims to find the best dose of a new drug called ivonescimab when used with standard chemotherapy for people newly diagnosed with extensive-stage small cell lung cancer. About 60 participants will receive one of two doses of ivonescimab along with carboplatin and etoposide chemotherapy. The goal is to see which dose is most effective and safest, as the drug is designed to help the immune system attack cancer and block tumor blood supply.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aspirus Cancer Center Wausau
RECRUITINGWausau, Wisconsin, 54401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.